​

Funding Round

Series B - Sudo Biosciences

Series B - Sudo Biosciences

Investment Firm

Overview

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Announced Date

Dec 20, 2023

Closed on Date

Dec 20, 2023

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

TPG

TPG

TPG is a debt and early_stage_venture and late_stage_venture and post_ipo and seed firm.

Enavate Sciences

Enavate Sciences

Enavate Sciences is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

6

Investor Name
Participant InvestorFrazier Life Sciences
Participant InvestorMonograph Capital
Participant Investor50 South Capital
Participant InvestorSanofi Ventures
Participant InvestorTPG

Round Details and Background

Sudo Biosciences raised $116000000 on 2023-12-20 in Series B

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 28, 2022
Series A - Sudo Biosciences
2-37.0M
Dec 20, 2023
Series B - Sudo Biosciences
9-116.0M
Feb 13, 2024
Series B - Sudo Biosciences
11-30.0M

Recent Activity

There is no recent news or activity for this profile.